JACC. Heart failure最新文献

{"title":"Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.","authors":"Ortal Tuvali, Rafael Kuperstein, Donna R Zwas, Igor Volodarsky, Edi Vaisbuch, Sara Shimoni, Jacob George, Sorel Goland","doi":"10.1016/j.jchf.2025.102702","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102702","url":null,"abstract":"<p><strong>Background: </strong>Data on the long-term clinical course of peripartum cardiomyopathy (PPCM) are limited.</p><p><strong>Objectives: </strong>This study aims to evaluate the long-term outcomes of patients with PPCM.</p><p><strong>Methods: </strong>The authors prospectively followed 119 women at 3 medical centers in Israel, of whom 96 had complete clinical and echocardiographic data and at least 3 years of follow-up observation and were included in the analysis.</p><p><strong>Results: </strong>The mean age at diagnosis was 31.6 ± 6.4 years, and the median left ventricular ejection fraction (LVEF) at presentation was 38% (Q1-Q3: 30%-43%). Of these patients, 76% achieved left ventricular recovery (defined as LVEF ≥50%), with a median LVEF of 55% (Q1-Q3: 49%-60%) at 1 year. The median follow-up period was 9.0 years (Q1-Q3: 6.1-13.8 years), 83% of women were followed for at least 5 years, and 40% for more than 10 years. During follow-up, 2 patients died of noncardiac causes, and the cause of death was unknown in 1. At long-term follow-up, LVEF was 56% (Q1-Q3: 50%-60%). Among the patients with LV recovery, 5 patients showed a decline in LVEF, and 5 of 23 patients with persistent LV dysfunction achieved LV recovery during long-term follow-up. Forty-six percent of patients received ≥1 cardiovascular medications during 10 years of follow-up evaluation. Of the 56 patients with a median LVEF of 58% (Q1-Q3: 55%-60%) who had subsequent pregnancies, 51 patients had full-term deliveries. No significant reduction in LVEF or increased cardiovascular comorbidities was observed at long-term follow-up.</p><p><strong>Conclusions: </strong>This study demonstrates favorable long-term outcomes in women with PPCM, low mortality, and stability of cardiac function. Subsequent pregnancies had no significant impact on their clinical course. During follow-up, cardiovascular comorbidities and medication use were documented for a substantial proportion of patients.</p>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":"102702"},"PeriodicalIF":11.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Preoperative Temporary Mechanical Circulatory Support on Durable LVAD Outcomes","authors":"Manreet K. Kanwar MD ,&nbsp;Palak Shah MD, MS ,&nbsp;Thomas Cascino MD ,&nbsp;Jonathan Grinstein MD ,&nbsp;Daniel Goldstein MD ,&nbsp;Jaime Hernandez-Montfort MD ,&nbsp;Song Li MD ,&nbsp;Nir Uriel MD ,&nbsp;Ezequiel Molina MD ,&nbsp;Ryan Cantor PhD ,&nbsp;Bhavana Komanduri MSPH ,&nbsp;Francis D. Pagani MD, PhD ,&nbsp;James K. Kirklin MD","doi":"10.1016/j.jchf.2025.102671","DOIUrl":"10.1016/j.jchf.2025.102671","url":null,"abstract":"<div><h3>Background</h3><div>An increasing number of patients undergoing durable left ventricular assist device (LVAD) implantation are supported with temporary mechanical circulatory support (tMCS) devices. The impact of tMCS on post-LVAD outcomes in the contemporary era is poorly described.</div></div><div><h3>Objectives</h3><div>This study aims to define characteristics and outcomes in patients undergoing LVAD implantation while on tMCS support from the Society of Thoracic Surgeons Intermacs (Interagency Registry for Mechanically Assisted Circulatory Support) database. The authors hypothesized that mortality rates and adverse events would vary based on tMCS type.</div></div><div><h3>Methods</h3><div>Adult patients who underwent implantation of a fully magnetically levitated LVAD from 2020 to 2024 as Intermacs profiles 1-3 were included. Primary outcomes analyzed were 1- and 2-year mortality and rates of stroke. Outcomes were compared in cohorts with no tMCS, intra-aortic balloon pump (IABP), high-flow micro-axial flow pump (HF-MP), and veno-arterial extracorporeal membrane oxygenation. A multivariable proportional hazards model was used to determine preoperative and perioperative characteristics associated with patient survival. A propensity score matching (PSM) analysis was performed to compare HF-MP with no tMCS.</div></div><div><h3>Results</h3><div>A total of 5,787 LVAD patients met inclusion criteria; 3,863 (66.7%) were supported on tMCS at the time of LVAD implantation. The use of the HF-MP increased significantly over the study period (19.1% to 35.1%, <em>P</em> &lt; 0.001) whereas the use of IABP decreased (41.2% to 27.3%, <em>P</em> &lt; 0.001). Overall patient survival was 82.9% and 77.9% at 1 and 2 years, respectively. Patients on extracorporeal membrane oxygenation had the lowest 1- and 2-year survival (70.6% and 67.1%) whereas patients on IABP (85.7% and 81.2%) and HF-MP (82.9% and 77.5%) had survival rates comparable to patients without tMCS therapy (82.4% and 77%, respectively). In the adjusted multivariable model, both HF-MP (HR: 0.71 [95% CI: 0.59-0.84]; <em>P</em> = 0.001) and IABP (HR: 0.74 [95% CI: 0.63-0.86]; <em>P</em> = 0.001) were associated with improved survival compared to no tMCS. In the propensity score matching cohort, rates of survival at 1 and 2 years were 85.2% vs 80.5%, respectively, and 79.9% vs 74.3% for HF-MP, respectively, vs no tMCS therapy (<em>P</em> = 0.009), whereas rates of freedom from stroke at 1 year were similar at 93.1% and 93.9% (<em>P</em> = 0.33), respectively.</div></div><div><h3>Conclusions</h3><div>An increasing number of patients undergoing durable LVAD are supported on tMCS at the time of implantation. Use of HF-MP and IABP were associated with improved survival and equivalent rate of stroke compared to no tMCS.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102671"},"PeriodicalIF":11.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145267643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction","authors":"Melana Yuzefpolskaya MD ,&nbsp;Howard J. Eisen MD","doi":"10.1016/j.jchf.2025.102678","DOIUrl":"10.1016/j.jchf.2025.102678","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102678"},"PeriodicalIF":11.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145267642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SCAI Is Not the Limit: Refining Dynamic Shock Trajectories With Machine Learning-Based Phenotyping.","authors":"Faraz S Ahmad,Ramsey M Wehbe,Jane E Wilcox","doi":"10.1016/j.jchf.2025.102700","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102700","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"26 1","pages":"102700"},"PeriodicalIF":13.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life's Essential 8 and Incident Heart Failure Among REGARDS Participants With and Without Diabetes.","authors":"Yulia Khodneva,Andrea L Cherrington,Pankaj Arora,Jessica Blair,Monika M Safford,Ro-Jay Reid,Madeline R Sterling,Megan Nordberg,Parag Goyal,Emily B Levitan","doi":"10.1016/j.jchf.2025.102686","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102686","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"86 1","pages":"102686"},"PeriodicalIF":13.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes","authors":"Felix Lindberg MD, PhD ,&nbsp;Carin Corovic Cabrera MD, PhD ,&nbsp;Lina Benson MS ,&nbsp;Ulrika Löfström MD ,&nbsp;Krister Lindmark MD, PhD ,&nbsp;Camilla Hage PhD ,&nbsp;Giulia Ferrannini MD, PhD ,&nbsp;Charlotta Ljungman MD, PhD ,&nbsp;Stephan Von Haehling MD, PhD ,&nbsp;Javed Butler MD, PhD ,&nbsp;John G.F. Cleland MD, PhD ,&nbsp;Stefan D. Anker MD, PhD ,&nbsp;Lars H. Lund MD, PhD ,&nbsp;Gianluigi Savarese MD, PhD","doi":"10.1016/j.jchf.2025.102662","DOIUrl":"10.1016/j.jchf.2025.102662","url":null,"abstract":"<div><h3>Background</h3><div>How iron deficiency (ID) is defined in heart failure (HF) may affect ID prevalence, associated prognosis, and achievable intravenous iron benefit.</div></div><div><h3>Objectives</h3><div>This study assessed 4 definitions of ID in heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) and evaluated prevalence, associated health-related quality of life (HR-QoL), symptoms, and cause-specific morbidity and mortality.</div></div><div><h3>Methods</h3><div>Patients enrolled in the Swedish HF Registry from 2017 to 2023 were included. ID was defined as follows: 1) in current HF guidelines; 2) in the IRONMAN (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency) trial; 3) with transferrin saturation (TSAT) &lt;20%; and 4) with a ferritin value &lt;100 μg/L.</div></div><div><h3>Results</h3><div>Of 20,673 patients (median age 74 years [Q1-Q3: 65-80 years]; 32% female), 49% fulfilled guideline ID criteria (HFrEF, 48%; HFmrEF, 48%; HFpEF, 54%), 53% fulfilled IRONMAN criteria (HFrEF, 52%; HFmrEF, 52%; HFpEF, 59%), 36% had TSAT &lt;20% (HFrEF, 36%; HFmrEF, 34%; HFpEF, 41%), and 37% has a ferritin level &lt;100 μg/L (HFrEF, 35%; HFmrEF, 37%; HFpEF, 42%). All definitions were independently associated with worse symptoms, and all except ferritin &lt;100 μg/L were associated with worse HR-QoL. TSAT &lt;20% and IRONMAN ID criteria were independently associated with a higher risk of all outcomes, including cardiovascular or all-cause death and HF or all-cause/cardiovascular/noncardiovascular hospitalizations. Guidelines-defined ID was independently associated only with outcomes containing HF hospitalizations or total all-cause hospitalizations, and ferritin &lt;100 μg/L was associated with no outcome. TSAT &lt;20% and IRONMAN ID criteria had stronger associations in HFpEF for outcomes containing HF hospitalization (<em>P</em> interaction &lt; 0.05). TSAT &lt;20% showed the greatest prognostic associations and discrimination.</div></div><div><h3>Conclusions</h3><div>Irrespective of definition, ID was highly prevalent (highest in HFpEF) and independently associated with worse symptoms or HR-QoL. ID defined as TSAT &lt;20% showed the strongest associations with outcomes, including mortality and HF or cardiovascular/noncardiovascular hospitalizations, likely representing the preferred definition with which to enroll a higher-risk group in trials.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102662"},"PeriodicalIF":11.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure","authors":"Jelani K. Grant MD, MHS ,&nbsp;Sui Zhang MS ,&nbsp;Sadiya S. Khan MD, MSc ,&nbsp;Bige Ozkan MD, ScM ,&nbsp;Vanessa Blumer MD ,&nbsp;Vijay Nambi MD ,&nbsp;Justin B. Echouffo-Tcheugui MD, PhD ,&nbsp;Ambarish Pandey MD ,&nbsp;Roger S. Blumenthal MD ,&nbsp;Christie M. Ballantyne MD ,&nbsp;Elizabeth Selvin PhD, MPH ,&nbsp;Kunihiro Matsushita MD, PhD ,&nbsp;Amil Shah MD, MPH ,&nbsp;Josef Coresh MD, PhD ,&nbsp;Chiadi E. Ndumele MD, PhD","doi":"10.1016/j.jchf.2025.102659","DOIUrl":"10.1016/j.jchf.2025.102659","url":null,"abstract":"<div><h3>Background</h3><div>The association of PREVENT-HF (Predicting Risk of Cardiovascular Events–Heart Failure) risk estimates with preclinical heart failure (HF) and whether preclinical HF measures add to the predictive utility of PREVENT-HF remain undefined.</div></div><div><h3>Objectives</h3><div>The aims of this study were to evaluate the association between PREVENT-HF risk estimates and preclinical HF, to examine how preclinical HF measures correspond to absolute HF risk within PREVENT-HF categories, and to determine whether they provide predictive value beyond the PREVENT-HF score.</div></div><div><h3>Methods</h3><div>The authors performed a prospective analysis of 2,714 ARIC (Atherosclerosis Risk In Communities) Visit 5 participants &lt;80 years of age, without baseline cardiovascular disease. Preclinical HF was defined by elevated cardiac biomarkers (N-terminal of pro-b-type natriuretic peptide ≥125 pg/mL or high-sensitivity cardiac troponin T ≥22 ng/L/≥14 ng/L in men/women) and/or abnormal echocardiographic findings. Within PREVENT-HF 10-year risk categories (&lt;7.5%, ≥7.5% to &lt;10%, ≥10% to &lt;15%, ≥15% to &lt;20%, and ≥20%), we assessed preclinical HF prevalence and compared 10-year HF incidence rates for those with and without preclinical HF. We assessed changes in predictive utility by adding preclinical HF measures to PREVENT-HF.</div></div><div><h3>Results</h3><div>The mean age was 74 years, with 63% women, and 22% Black adults. Higher PREVENT-HF risk was associated with higher preclinical HF prevalence, with the highest prevalence of combined elevated biomarkers plus abnormal echocardiograms (37%) in those with PREVENT-HF ≥20%. Over a median follow-up of 9.9 years, 262 HF events occurred. Within PREVENT-HF categories, preclinical HF measures were strongly associated with absolute HF risk: among those with PREVENT-HF ≥20%, HF incidence rates (per 1,000 person-years) were 9.5 with no preclinical HF and 51.5 with elevated biomarkers plus abnormal echocardiography. Adding cardiac biomarkers to PREVENT-HF improved risk discrimination (C statistic change 0.69 to 0.75; <em>P &lt;</em> 0.001) and reclassification (categorical Net Reclassification Index: 0.17; 95% CI: 0.09-0.26), with modest further improvement from adding echocardiographic measures.</div></div><div><h3>Conclusions</h3><div>Preclinical HF measures indicate higher absolute HF risk within PREVENT-HF categories and enhance HF risk prediction.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102659"},"PeriodicalIF":11.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide and Exercise Function in Obesity-Related HFpEF","authors":"Barry A. Borlaug MD ,&nbsp;Dalane W. Kitzman MD ,&nbsp;Shachi Patel PhD ,&nbsp;Khaja M. Chinnakondepalli MS ,&nbsp;Javed Butler MD ,&nbsp;Melanie J. Davies MD ,&nbsp;Mark C. Petrie MD ,&nbsp;Sanjiv J. Shah MD ,&nbsp;Subodh Verma MD, PhD ,&nbsp;Julio Núñez MD ,&nbsp;Mette Nygaard Einfeldt MD, PhD ,&nbsp;Karoline Liisberg MSc ,&nbsp;Afshin Salsali MD ,&nbsp;Mikhail N. Kosiborod MD ,&nbsp;STEP-HFpEF Trial Committees and Investigators","doi":"10.1016/j.jchf.2025.102660","DOIUrl":"10.1016/j.jchf.2025.102660","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Exercise function quantified by 6-minute walk distance (6MWD) is severely impaired in patients with heart failure with preserved ejection fraction (HFpEF).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This prespecified secondary analysis of pooled data from the STEP-HFpEF Program (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) examined factors associated with impaired exercise function at baseline, detailed effects of semaglutide on 6MWD, and on other key trial endpoints according to baseline 6MWD in patients with HFpEF.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Associates of 6MWD were assessed at baseline, and effects of semaglutide on 6MWD were evaluated at early (20 weeks) and final (52 weeks) time points, across subgroups, and according to the magnitude of weight loss achieved. Effects of semaglutide on the dual primary (changes in Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score [KCCQ-CSS] and body weight) and secondary/exploratory endpoints were contrasted by tertiles of baseline 6MWD.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The authors randomized 1,145 patients to semaglutide or placebo. Compared with patients who had obesity-related HFpEF and higher 6MWD, those with lower 6MWD were older and had lower KCCQ-CSS, higher body mass index and waist circumference, greater systemic inflammation (higher C-reactive protein), and more severe congestion (higher N-terminal pro–B-type natriuretic peptide, more diuretic use). Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m; &lt;em&gt;P&lt;/em&gt; &lt; 0.0001]) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m; &lt;em&gt;P&lt;/em&gt; &lt; 0.0001]). Increases in 6MWD with semaglutide (vs placebo) were similar across all relevant subgroups, with no significant interactions. Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro–B-type natriuretic peptide across the spectrum of baseline 6MWD (all &lt;em&gt;P&lt;/em&gt;&lt;sub&gt;interaction&lt;/sub&gt; = NS). Each 1-unit decrease in body mass index on treatment with semaglutide was associated with a 4.1 m (95% CI: 2.4-5.7 m) increase in 6MWD (&lt;em&gt;P&lt;/em&gt; &lt; 0.0001).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss. The effects were consistent across subgroups. There was strong correlation between greater magnitude of weight loss and greater improvements ","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102660"},"PeriodicalIF":11.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors After Preeclampsia","authors":"Rossana Orabona MD ,&nbsp;Edoardo Sciatti MD ,&nbsp;Federico Prefumo MD, PhD ,&nbsp;Marc E.A. Spaanderman MD, PhD ,&nbsp;Michele Senni MD ,&nbsp;Rudolf A. de Boer MD, PhD ,&nbsp;Chahinda Ghossein-Doha MD, PhD","doi":"10.1016/j.jchf.2025.102688","DOIUrl":"10.1016/j.jchf.2025.102688","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102688"},"PeriodicalIF":11.8,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal Heart Failure","authors":"Joan E. Briller MD","doi":"10.1016/j.jchf.2025.102664","DOIUrl":"10.1016/j.jchf.2025.102664","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 10","pages":"Article 102664"},"PeriodicalIF":11.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145083427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}